<DOC>
	<DOCNO>NCT02836821</DOCNO>
	<brief_summary>The primary purpose study investigate potential pharmacokinetic interaction healthy volunteer apatinib administer combination rifampicin . Secondary objective evaluate safety tolerability apatinib alone co-administered rifampicin .</brief_summary>
	<brief_title>Effect Rifampicin Pharmacokinetics Apatinib</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>female nonchildbearing potential male ; age 1845 year ; body mass index 1924 kg/m2 total body weight ; clinically significant medical surgical condition potential interfere absorption , distribution , metabolism excretion study drug ; history alcohol abuse ; smoker ; electrocardiogram ( ECG ) abnormality ; blood pressure &gt; 140/90 mmHg ; treatment investigational drug know CYP450 enzyme inducing/inhibiting agent herbal supplement within 14 day prior first dose study medication ; Subjects abstain use prescription nonprescription drug ( acetaminophen deem necessary ) , vitamins dietary supplement within 14 day prior first dose study medication throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>